MGX
NASDAQMetagenomi Therapeutics Inc.
Price$1.20-0.02 (-1.23%)
04:30 PM07:45 PM
News · 26 weeks27+75%
2025-12-282026-06-21
Mix1790d
- Insider10(59%)
- SEC Filings4(24%)
- Other3(18%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Reid Laurence4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDERSEC Form 4 filed by Director Dere Willard H4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDERSEC Form 4 filed by Director Bjerkholt Eric4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDERSEC Form 4 filed by Director Eckhardt Juergen4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDERChief Financial Officer Wapnick Pamela sold $3,746 worth of shares (2,884 units at $1.30), decreasing direct ownership by 1% to 208,491 units (SEC Form 4) to satisfy withholding tax4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDEROfficer Irish Jian sold $4,854 worth of shares (3,737 units at $1.30), decreasing direct ownership by 0.98% to 377,533 units (SEC Form 4) (for tax liability)4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDEROfficer Wein Matthew sold $725 worth of shares (558 units at $1.30), decreasing direct ownership by 0.44% to 126,491 units (SEC Form 4) to satisfy withholding tax4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- PRMetagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare ConferenceEMERYVILLE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the Jefferies Global Healthcare Conference, being held in New York, NY, on Thursday, June 4, 2026, at 7:35 a.m. ET. The fireside chat presentation will be made available on the "News & Events" page in the Investors section of the Company's website at https://ir.metagenomi.co/news-events/events. About Metagenomi
- SECSEC Form 10-Q filed by Metagenomi Therapeutics Inc.10-Q - Metagenomi Therapeutics, Inc. (0001785279) (Filer)
- SECMetagenomi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Metagenomi Therapeutics, Inc. (0001785279) (Filer)
- PRMetagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial ResultsOn track for regulatory submission of MGX-001 to advance global clinical program, including investigational new drug application ("IND") in 4Q 2026 Publication in Nature Structural & Molecular Biology highlights potential of MG119-28, a proprietary compact CRISPR nuclease with enhanced genome editing efficiency $140.2 million in cash, cash equivalents, and available-for-sale marketable securities as of March 31, 2026, with runway anticipated to support operations through 4Q 2027 EMERYVILLE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative
- SECSEC Form DEFA14A filed by Metagenomi Therapeutics Inc.DEFA14A - Metagenomi Therapeutics, Inc. (0001785279) (Filer)
- SECSEC Form DEF 14A filed by Metagenomi Therapeutics Inc.DEF 14A - Metagenomi Therapeutics, Inc. (0001785279) (Filer)
- PRMetagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing EfficiencyEMERYVILLE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced a publication in Nature Structural & Molecular Biology highlighting the discovery and detailed characterization of MG119-28, a compact CRISPR nuclease with superior editing efficiency relative to previously identified compact nucleases. The publication, titled "Comparative characterization of Cas12f orthologs reveals mechanistic features underlying enhanced genome editing efficiency" highlights the potential of MG119-28 (formally na
- INSIDERSEC Form 4 filed by Irish Jian4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDERSEC Form 4 filed by Wein Matthew4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDERSEC Form 4 filed by Wapnick Pamela4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDERChief Financial Officer Wapnick Pamela sold $2,530 worth of shares (1,581 units at $1.60), decreasing direct ownership by 0.84% to 187,375 units (SEC Form 4)4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDEROfficer Wein Matthew sold $771 worth of shares (482 units at $1.60), decreasing direct ownership by 0.42% to 114,549 units (SEC Form 4)4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- INSIDERChief Executive Officer Irish Jian gifted 228,462 shares and sold $2,571 worth of shares (1,607 units at $1.60), decreasing direct ownership by 41% to 333,770 units (SEC Form 4)4 - Metagenomi Therapeutics, Inc. (0001785279) (Issuer)
- SECSEC Form S-8 filed by Metagenomi Therapeutics Inc.S-8 - Metagenomi Therapeutics, Inc. (0001785279) (Filer)
- SECSEC Form 10-K filed by Metagenomi Therapeutics Inc.10-K - Metagenomi Therapeutics, Inc. (0001785279) (Filer)
- SECMetagenomi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Metagenomi Therapeutics, Inc. (0001785279) (Filer)
- PRMetagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial ResultsCompleted pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investigational new drug application ("IND") in 4Q 2026 Announced corporate name change to Metagenomi Therapeutics, Inc. to reflect Company's strategic evolution $160.8 million in cash, cash equivalents and available-for-sale marketable securities as of December 31, 2025 with runway anticipated to support operations through 4Q 2027 EMERYVILLE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on it
- PRMetagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare ConferenceEMERYVILLE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the 46th Annual TD Cowen Healthcare Conference, being held in Boston, MA, on Monday, March 2, 2026 at 11:10 a.m. ET. The fireside chat presentation will be made available on the "News & Events" page in the Investors section of the Company's website at https://ir.metagenomi.co/news-events/events. About Metageno
MGX FAQ
6 questionsWhere does MGX stock trade?
Metagenomi Therapeutics Inc. (MGX) is listed on NASDAQ.What sector and industry is MGX in?
Metagenomi Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Metagenomi Therapeutics Inc. go public?
Metagenomi Therapeutics Inc. (MGX) completed its IPO in 2024.What are analysts saying about MGX?
Metagenomi Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1000.00 price target on 2024-05-07. Recent price targets range from $600.00 to $2500.00.What companies are similar to MGX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare MGX side-by-side with any of them on Quantisnow.How can I track MGX on Quantisnow?
Quantisnow aggregates Metagenomi Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MGX to receive live email and push alerts on every new disclosure.